Upatinib for anal fistulas in Crohn's disease
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This trial tests whether upatinib can help heal active anal fistulas in people with moderate to severe Crohn's disease. If you have an anal fistula that is causing pain or drainage, this study may offer a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have moderate to severe Crohn's disease (CDAI score over 220)
- You have an active anal fistula (causing pain or fluid leaking) confirmed by MRI
- You have had a blood clot before (like in a leg, lung, or brain)
- You do not have a history of blood clots
- You agree to participate and sign the consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
This study is looking at how well the drug upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis. It is not a treatment trial, but will observe patients who are already taking upadacitinib as decided by their doctor.
This study tests an oral pill called upadacitinib for children with moderate to severe Crohn's disease that hasn't responded well to other treatments. It aims to see if the medicine can reduce inflammation and improve symptoms safely.
This trial tests a medication called upadacitinib for people hospitalized with a severe ulcerative colitis flare. It could help control inflammation and reduce symptoms.
This study is for people with moderate to severe Crohn's disease who are starting a medication called upadacitinib. Researchers will watch how the disease changes over time and check for any side effects. It's an observational study, meaning you'll keep getting your regular treatment.
This trial tests if a higher dose of upadacitinib can help people with ulcerative colitis who stopped responding to the 30 mg daily dose. It aims to see if re-inducing with a stronger dose can bring back symptom control.
Hear when a new Crohn's Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.